Enablex Articles
Novartis sells US rights to the overactive bladder drug Enablex to Warner Chilcott for $400 million plus
26 September 2010
Watson seeking to market generic Enablex in USA; Novartis files patent infringement suit
30 April 2009
P&G looking to sell pharma operations
16 February 2009
Stock Commentary - New York week to Dec 15, 2008
22 December 2008
Beijing Med-Pharm to market Enablex in China
3 December 2007
Ardana's fiscal 2007 loss per share widens 28.6%
9 July 2007
Ardana/Novartis commence marketing Emselex in UK
27 November 2006
Novartis to develop Enablex in USA with P&G
18 July 2005
Emselex increases dry days for OAB patients
28 March 2005
Enablex in elderly: no cognition impairment
7 March 2005
Novartis' Enablex cleared for OAB in USA
10 January 2005
Emselex shows good safety profile
6 September 2004
Novartis' Emselex on track in EU
9 August 2004
Novartis' Enablex improves quality of life
5 July 2004
Positive findings for Novartis' Enablex
20 October 2003
Novartis' Enablex on track for 2004 appro
13 October 2003
Stock Commentary - Europe
31 March 2003
Further progress for Pfizer/Pharmacia deal
31 March 2003
Stock Commentary - New York
31 March 2003
Rheumatoid Arthritis And Disease Management
22 April 1996
New York Stock Comment
16 October 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Pfizer Expects A Strong Performance In 1995
2 October 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Pfizer's Enablex Slows Progression of Arthritis
31 October 1994
Pfizer: Record Number Of Drugs In Phases II & III
31 October 1994
First Approval For Enablex
10 October 1994
NEW DRUG OPTION FOR ARTHRITIS THERAPY
19 July 1993
PFIZER "CONFIDENT" IN CHANGING ENVIRONMENT
3 May 1993
Showing 1-33 of 33 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
